Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intracavernous prostaglandin E1 in erectile dysfunction

O I Linet1, L L Neff

  • 1Upjohn Company, Kalamazoo.

The Clinical Investigator
|January 1, 1994
PubMed
Summary

Prostaglandin E1 (PGE1) effectively treats erectile dysfunction, inducing erections in 70-80% of patients. Careful dosing and patient education minimize risks like prolonged erections, making PGE1 a valuable therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment.

Urology·2001
Same author

Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa.

International journal of impotence research·1999
Same author

Quality of life effects of alprostadil therapy for erectile dysfunction.

The Journal of urology·1997
Same author

Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.

The New England journal of medicine·1996
Same author

Evaluation of real-time RigiScan monitoring in pharmacological erection.

The Journal of urology·1995
Same author

Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: phase II-open study.

Prostaglandins·1991

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Prostaglandin E1 (PGE1) is a naturally occurring substance found in mammalian tissues.
  • PGE1 has been extensively studied for its role in diagnosing and treating erectile dysfunction (ED).

Purpose of the Study:

  • To review the diagnostic and therapeutic applications of Prostaglandin E1 in managing erectile dysfunction.
  • To assess the efficacy, contraindications, and side effects associated with PGE1 treatment for ED.

Main Methods:

  • Literature review of published data on PGE1 use in erectile dysfunction.
  • Analysis of efficacy rates, contraindications, and adverse events reported in clinical studies.

Main Results:

  • PGE1 (10-20 micrograms) achieves full erections in 70-80% of ED patients.
  • Common side effects include injection site pain (16.8%) and hematoma (1.5%).
  • Prolonged erection/priapism occurs in 1.3% of patients but can be managed with dose titration and education.

Conclusions:

  • PGE1 is a minimally invasive and effective treatment for organic and psychogenic erectile dysfunction.
  • Contraindications include sickle cell anemia, coagulopathy, and severe psychiatric disorders.
  • Long-term monitoring for side effects like fibrosis is recommended with extended PGE1 use.

Related Experiment Videos